Nyxoah S.A.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Olivier Taelman
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Rue Edouard Belin 12 Mont-Saint-Guibert WA Belgium 1435
- IPO Date
- Apr 28, 2021
- CIK
- 0001857190
- Website
- nyxoah.com
- Similar Companies
- Business
- Nyxoah SA (NYXH) is a medical technology company focused on the development and commercialization of innovative neurostimulation solutions to treat obstructive sleep apnea (OSA). The company's lead product is the Genio system, a minimally invasive, patient-centered hypoglossal nerve stimulation therapy for adult patients with moderate to severe OSA who are intolerant of, non-compliant with, or have failed continuous positive airway pressure therapy; it features a bilateral implantable neurostimulator, wireless external activation chip, and disposable patient-controlled patches. Nyxoah markets the CE-marked Genio system across Europe and select international markets, with research, development, and manufacturing primarily based in Israel; it was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. In August 2025, the US Food and Drug Administration approved the Genio system for OSA treatment, supporting the company's strong US commercial launch reported in the third quarter of 2025. Nyxoah recently secured financing commitments of up to $77 million to accelerate US commercialization and expanded its presence in the Middle East through partnerships in Abu Dhabi, Dubai, and Kuwait following the region's first Genio implant.
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Nyxoah SA (NYXH) Analyst/Investor Day Transcript
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Information on the total number of voting rights and shares
Publication relating to transparency notifications
Nyxoah to Host Investor Day in New York on July 8, 2026
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026
Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 9 juillet 2026
Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026
Publication relating to transparency notifications
Nyxoah Receives $15 Million from the European Investment Bank
Information on the total number of voting rights and shares
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
Nyxoah Announces Closing of Underwritten Public Offering
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
Nyxoah Announces Proposed Offering of Ordinary Shares
Nyxoah Enters New Chapter of Long Term Value Creation
Information on the total number of voting rights and shares
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah SA (NYXH) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript